title: Considerations for clinical trial design and data analyses of thorough QT studies using drug-drug interaction.
authors.affiliation: Division of Pharmacometrics, Office of Clinical Pharmacology, CDER, Food and Drug Administration, 10903 New Hampshire Avenue, Room 3150, Building 51, Silver Spring 20993, USA. Hao.Zhu@fda.hhs.gov
authors.forename: Hao
authors.initials: H
authors.lastname: Zhu
authors.forename: Yaning
authors.initials: Y
authors.lastname: Wang
authors.forename: Jogarao V
authors.initials: JV
authors.lastname: Gobburu
authors.forename: Christine E
authors.initials: CE
authors.lastname: Garnett
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods; D004347:Drug Interactions; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced*